Cor Vasa 2013, 55(3):360-363

13. komnata fibrilace síní? Ischemická cévní mozková příhoda!

Published: June 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
13. komnata fibrilace síní? Ischemická cévní mozková příhoda! Cor Vasa. 2013;55(3):360-363.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pradaxa® SPC 2013.
    2. K.K. Andersen, T.S. Olsen, C. Dehlendorff, L.P. Kammersgaard, Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors, Stroke 40 (2009) 2068-2072. Go to original source... Go to PubMed...
    3. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, et al., Newly identified events in the RE-LY trial, The New England Journal of Medicine 363 (2010) 1875-1876. Go to original source... Go to PubMed...
    4. Pradaxa® SPC 2012.
    5. M.R. Patel, K.W. Mahaffey, J. Garg, et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, The New England Journal of Medicine 365 (2011) 883-891. Go to original source... Go to PubMed...
    6. C.B. Granger, J.H. Alexander, J.J. McMurray, et al., Apixaban versus warfarin in patients with atrial fibrillation, The New England Journal of Medicine 365 (2011) 981-992. Go to original source... Go to PubMed...
    7. R. Čihák, L. Haman, P. Heinc, Summary of the 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Prepared by the Czech Society of Cardiology, Cor et Vasa 54 (2012) e341-e351. Go to original source...
    8. M. Huismann, G.Y. Lip, H.C. Diener, et al., Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice, Thrombosis and Haemostasis 107 (2012) 838-847. Go to original source... Go to PubMed...
    9. J. Eikelboom, L. Wallentin, S.J. Connolly, et al., Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial, Circulation 123 (2011) 2363-2372. Go to original source... Go to PubMed...
    10. J. Stangier, K. Rathgen, H. Stähle, et al., The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects, British Journal of Clinical Pharmacology 64 (2007) 292-303. Go to original source... Go to PubMed...
    11. A. Clemens, S. Haertter, J. Friedman, et al., Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification, Current Medical Research and Opinion 28 (2012) 195-201. Go to original source... Go to PubMed...
    12. A.J. Claxton, J. Cramer, C. Pierce, A systematic review of the associations between dose regimens and medication compliance, Clinical Therapeutics 23 (2001) 1296-1310. Go to original source... Go to PubMed...
    13. D.S. Budnitz, M.C. Lovegrove, N. Shehab, C.L. Richards, Emergency hospitalizations for adverse drug events in older Americans, The New England Journal of Medicine 365 (2011) 2002-2012. Go to original source... Go to PubMed...
    14. M.R. Southworth, M.E. Reichman, E.F. Unger, Dabigatran and postmarketing reports of bleeding, The New England Journal of Medicine 368 (2013) 1272-1274. Go to original source... Go to PubMed...
    15. R. Nagarakanti, M.D. Ezekowitz, J. Oldgren, et al., Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion, Circulation 123 (2011) 131-136. Go to original source... Go to PubMed...
    16. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm282820.htm
    17. L. Dans, S.J. Connolly, L. Wallentin, et al., Concomitant use of antiplatelet therapy with dabigatran or warfarin in RE-LY trial, http://circ.ahajournals.org/content/early/2012/12/27/CIRCULATIONAHA.112.115386
    18. S.H. Hohnloser, J. Oldgren, S. Yang, et al., Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial, Circulation 125 (5) (2012) 669-676. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes